{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:17:02Z","timestamp":1788322622729,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Science Fund of the Republic of Serbia","award":["6060866"],"award-info":[{"award-number":["6060866"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Development of lymphoproliferative disorders (LPDs) is one of the well-known life-threatening complications in rheumatoid arthritis (RA) patients. However, there is a lack of definitive conclusions regarding the role of Epstein-Barr virus (EBV) activity in RA initiation and progression, especially in promoting LPDs. A systematic review and meta-analysis of studies that reported an EBV positive result in RA-LPD patients and controls were conducted. Studies published before 27 July 2021 were identified through PubMed, Web of Science, and SCOPUS. A total of 79 articles were included in the systematic review. The prevalence of EBV positive result among RA-LPD patients was 54% (OR = 1.54, 95% CI = 1.45\u20131.64). There was a statistically significant association between EBV presence and LPD susceptibility in RA patients in comparison with all controls (OR = 1.88, 95% CI = 1.29\u20132.73) and in comparison with LPD patients only (OR = 1.92, 95% CI = 1.15\u20133.19). This association was not shown in comparison with patients with autoimmune diseases other than RA who developed LPD (OR = 0.79, 95% CI = 0.30\u20132.09). This meta-analysis confirmed a high prevalence of EBV in the RA-LPD population. Furthermore, it provides evidence for the association between EBV presence and LPD susceptibility in RA patients, but not in those with other autoimmune diseases who developed LPD.<\/jats:p>","DOI":"10.3390\/v14010115","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T23:35:09Z","timestamp":1641771309000},"page":"115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["New Evidence of Significant Association between EBV Presence and Lymphoproliferative Disorders Susceptibility in Patients with Rheumatoid Arthritis: A Systematic Review with Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6829-096X","authenticated-orcid":false,"given":"Ana","family":"Banko","sequence":"first","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-8701","authenticated-orcid":false,"given":"Danijela","family":"Miljanovic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6795-1378","authenticated-orcid":false,"given":"Ivana","family":"Lazarevic","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Jeremic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8137-911X","authenticated-orcid":false,"given":"Aleksa","family":"Despotovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milka","family":"Grk","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andja","family":"Cirkovic","sequence":"additional","affiliation":[{"name":"Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1038\/s41598-018-22058-6","article-title":"Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis","volume":"8","author":"Trier","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1080\/10428194.2019.1585841","article-title":"Clinicopathological features of clinical methotrexate-related lymphoproliferative disorders","volume":"60","author":"Tokuhira","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","article-title":"Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population","volume":"52","author":"Mercer","year":"2013","journal-title":"Rheumatology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Takada, H., Kaneko, Y., Nakano, K., Tanaka, M., Fujii, T., Saito, K., Sugimoto, N., Sasaki, S., Saito, S., and Saito, R. (2021). Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study. Mod. Rheumatol., 1\u20139.","DOI":"10.1080\/14397595.2021.1899570"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","article-title":"Cytokines in rheumatoid arthritis-shaping the immunological landscape","volume":"12","author":"McInnes","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1158\/1055-9965.EPI-06-0300","article-title":"Malignant lymphomas in autoimmunity and inflammation: A review of risks, risk factors, and lymphoma characteristics","volume":"15","author":"Smedby","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/cas.13249","article-title":"Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: Comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types","volume":"108","author":"Gion","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2017.1352477","article-title":"Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: A review of the literature and current perspective","volume":"28","author":"Harigai","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/00365513.2018.1550807","article-title":"Increased antibody levels to stage-specific Epstein\u2013Barr virus antigens in systemic autoimmune diseases reveal a common pathology","volume":"79","author":"Draborg","year":"2019","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus exploiting the immune system","volume":"1","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Balandraud, N., Texier, G., Massy, E., Muis-Pistor, O., Martin, M., Auger, I., Guzian, M.C., Guis, S., Pham, T., and Roudier, J. (2017). Long term treatment with Abatacept or Tocilizumab does not increase Epstein-Barr Virus load in patients with Rheumatoid arthritis\u2014A three years retrospective study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0171623"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13075-015-0755-6","article-title":"Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis","volume":"17","author":"Ball","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","article-title":"Epstein-Barr Virus and Systemic Autoimmune Diseases","volume":"11","author":"Houen","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., and Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med., 6.","DOI":"10.2427\/5768"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref_17","unstructured":"Wells, G., Shea, B., O\u2019connell, D., and Peterson, J.W. (2021, December 05). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online:   http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Higgins, J.P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons.","DOI":"10.1002\/9781119536604"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 Years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: Histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/his.12627","article-title":"Clinicopathological characteristics and rituximab addition to cytotoxic therapies in patients with rheumatoid arthritis and methotrexate-associated large B lymphoproliferative disorders","volume":"67","author":"Yamada","year":"2015","journal-title":"Histopathology"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hwang, J., Suh, C.H., Kim, K.W., Kim, H.S., Armand, P., Huang, R.Y., and Guenette, J.P. (2021). The incidence of epstein-barr virus-positive diffuse large b-cell lymphoma: A systematic review and meta-analysis. Cancers, 13.","DOI":"10.3390\/cancers13081785"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00428-016-2030-x","article-title":"Epstein\u2013Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders","volume":"470","author":"Oshiro","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein-Barr virus by methotrexate: A potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar2708","article-title":"Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies","volume":"11","author":"Gestermann","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jviromet.2007.08.010","article-title":"Forensic application of Epstein-Barr virus genotype: Correlation between viral genotype and geographical area","volume":"147","author":"Ikegaya","year":"2008","journal-title":"J. Virol. Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/10428194.2012.715347","article-title":"Low incidence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in Tianjin, northern China","volume":"54","author":"Pan","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/modpathol.2011.62","article-title":"Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: A comparative analysis of a Mexican and a German population","volume":"24","author":"Hofscheier","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1055-9965.EPI-06-0353","article-title":"The enigmatic epidemiology of nasopharyngeal carcinoma","volume":"15","author":"Chang","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.virusres.2009.07.005","article-title":"The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal","volume":"143","author":"Chang","year":"2009","journal-title":"Virus Res."},{"key":"ref_32","first-page":"365","article-title":"EBV and autoimmunity","volume":"390","author":"Ascherio","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/PAS.0000000000001271","article-title":"Methotrexate-associated Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis Clinicopathologic Features and Prognostic Factors","volume":"43","author":"Kurita","year":"2019","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/1\/115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:27:09Z","timestamp":1760362029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/1\/115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["v14010115"],"URL":"https:\/\/doi.org\/10.3390\/v14010115","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]}}}